Stockreport

Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF TARRYTOWN, N.Y. and PARIS, Oct. 16, 2018 /PRNewswire/ -- Dupixent significantly reduced nasal polyp size, nasal congestion severity and need for systemic corticosteroids [Read more]